COSMOS Pharmaceutical - Public Comps and Valuation Multiples

COSMOS Pharmaceutical Overview

About COSMOS Pharmaceutical

COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company places a emphasis on convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company’s revenue is derived from common grocery sales. Cosmos also operates a private grocery brand called ON 365.

Founded

1983

HQ

Employees

28.8K+

Website

cosmospc.co.jp

Sectors

Pharmacies

Financials

LTM Revenue $6.9B

LTM EBITDA $427M

EV

$3.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

COSMOS Pharmaceutical Financials

As of September 2025, COSMOS Pharmaceutical reported last 12-month revenue of $6.9B and EBITDA of $427M.

In the same period, COSMOS Pharmaceutical generated $1.5B in LTM gross profit and $210M in net income.

See COSMOS Pharmaceutical valuation multiples based on analyst estimates

COSMOS Pharmaceutical P&L

In the most recent fiscal year, COSMOS Pharmaceutical reported revenue of $6.7B and EBITDA of $430M.

COSMOS Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See COSMOS Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$6.9B	XXX	$6.7B	XXX	XXX	XXX
Gross Profit	$1.5B	XXX	$1.4B	XXX	XXX	XXX
Gross Margin	21%	XXX	21%	XXX	XXX	XXX
EBITDA	$427M	XXX	$430M	XXX	XXX	XXX
EBITDA Margin	6%	XXX	6%	XXX	XXX	XXX
EBIT	$275M	XXX	$268M	XXX	XXX	XXX
EBIT Margin	4%	XXX	4%	XXX	XXX	XXX
Net Profit	$210M	XXX	$205M	XXX	XXX	XXX
Net Margin	3%	XXX	3%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for COSMOS Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $6.9B. EBITDA for the last twelve months was $427M. In the most recent fiscal year, COSMOS Pharmaceutical achieved $6.7B in revenue and $430M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$6.9B	Analyst estimates available to subscribers	$6.7B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.5B	Analyst estimates available to subscribers	$1.4B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	21.2% gross margin	Analyst estimates available to subscribers	21.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$427M	Analyst estimates available to subscribers	$430M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	6.2% EBITDA margin	Analyst estimates available to subscribers	6.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$275M	Analyst estimates available to subscribers	$268M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	4.0% EBIT margin	Analyst estimates available to subscribers	4.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$210M	Analyst estimates available to subscribers	$205M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	3.1% net profit margin	Analyst estimates available to subscribers	3.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for COSMOS Pharmaceutical

This financial data table provides comprehensive performance metrics for COSMOS Pharmaceutical, a company based in Japan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

COSMOS Pharmaceutical generated $6.9B in revenue over the last twelve months.
The company achieved $427M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.5B.
Net income over the last twelve months reached $210M.

Fiscal Year Performance

In the most recent fiscal year, COSMOS Pharmaceutical reported $6.7B in total revenue.
Fiscal year EBITDA was $430M.
The company maintained a gross profit margin of 21.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 6.4%.
Net profit margin reached 3.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for COSMOS Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

COSMOS Pharmaceutical Stock Performance

COSMOS Pharmaceutical has current market cap of JPY 547B (or $3.6B), and EV of JPY 539B (or $3.6B).

Market Cap Evolution

COSMOS Pharmaceutical Stock Data

As of October 30, 2025, COSMOS Pharmaceutical's stock price is JPY 6900 (or $46).

See COSMOS Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.6B	$3.6B	XXX	XXX	XXX	XXX	$2.65

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

COSMOS Pharmaceutical Valuation Multiples

COSMOS Pharmaceutical's trades at 0.5x EV/Revenue multiple, and 8.9x EV/EBITDA.

See valuation multiples for COSMOS Pharmaceutical and 15K+ public comps

COSMOS Pharmaceutical Financial Valuation Multiples

As of October 30, 2025, COSMOS Pharmaceutical has market cap of $3.6B and EV of $3.6B.

Equity research analysts estimate COSMOS Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

COSMOS Pharmaceutical has a P/E ratio of 17.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.6B	XXX	$3.6B	XXX	XXX	XXX
EV (current)	$3.6B	XXX	$3.6B	XXX	XXX	XXX
EV/Revenue	0.5x	XXX	0.5x	XXX	XXX	XXX
EV/EBITDA	8.4x	XXX	8.9x	XXX	XXX	XXX
EV/EBIT	13.0x	XXX	14.7x	XXX	XXX	XXX
EV/Gross Profit	2.5x	XXX	n/a	XXX	XXX	XXX
P/E	17.3x	XXX	19.4x	XXX	XXX	XXX
EV/FCF	432.5x	XXX	-703.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get COSMOS Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

COSMOS Pharmaceutical Margins & Growth Rates

COSMOS Pharmaceutical's last 12 month revenue growth is 6%

COSMOS Pharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $40K for the same period.

COSMOS Pharmaceutical's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

COSMOS Pharmaceutical's rule of X is 22% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for COSMOS Pharmaceutical and other 15K+ public comps

COSMOS Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	6%	XXX	6%	XXX	XXX	XXX
EBITDA Margin	6%	XXX	6%	XXX	XXX	XXX
EBITDA Growth	7%	XXX	8%	XXX	XXX	XXX
Rule of 40	12%	XXX	12%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	22%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$40K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	17%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial